CompletedPhase 3NCT04308590

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Studying OBSOLETE: Cushing syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Corcept Therapeutics
Principal Investigator
Andreas Moraitis, MD
Corcept Therapeutics
Intervention
Relacorilant(drug)
Enrollment
137 enrolled
Eligibility
18-80 years · All sexes
Timeline
20202024

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04308590 on ClinicalTrials.gov

Other trials for OBSOLETE: Cushing syndrome

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Cushing syndrome

← Back to all trials